Shanghai Xinwei Medical Technology Co., Ltd. Receives CSRC Approval for Private Placement of Domestic Shares

HeartCare-B (06609) announced that the company has received the "Approval for the Registration of Shanghai HeartCare Medical Technology Co., Ltd. to Issue Shares to Specific Objects" (Approval No. [2026]1153) issued by the China Securities Regulatory Commission (CSRC) on May 14, 2026 (the date of approval registration). Accordingly, the CSRC has agreed that the company issue new domestic shares to subscribers under the subscription. Details of the approval are as follows:

1. The China Securities Regulatory Commission has approved the Company's registration application for issuing shares to specific objects.

2. The issuance must be strictly implemented in accordance with the submission documents filed with the China Securities Regulatory Commission.

3. This approval shall be valid for twelve months from the date of registration agreed by the China Securities Regulatory Commission.

4. From the date of approval by the China Securities Regulatory Commission (CSRC) until the completion of this issuance, if any significant matters occur in our company, we shall promptly report to the CSRC and handle them in accordance with relevant regulations.